论文部分内容阅读
目的观察CT引下经皮穿刺癌灶内注射无水乙醇碘油乳利(Percutaneous Ethanol-Lipiodol Injection,PELI)配合肝动脉化疗栓塞(transcatherter arterlal chemoembolization,TACE)治疗肝癌的疗效。方法64例原发性肝癌患者被随机分为两组。其中32例作为研究组接受TACE+经皮瘤内注射无水乙醇-碘油乳剂治疗;另外32例作为对照组,接受单纯TACE治疗。两组患者的Child分级无显著差异(P>0.05)。结果治疗结束3个月后比较患者治疗前后AFP降低程度和肿块缩小情况,差异有显著性(P<0.05),研究组和对照组1、2年生存率分别为96%/78%和81%/48%。结论PELI配合TACE治疗原发性肝癌较单纯TACE治疗具有更好的临床疗效。
Objective To observe the curative effect of Percutaneous Ethanol-Lipiodol Injection (PELI) combined with transcatherter arterial chemoembolization (TACE) for the treatment of liver cancer under percutaneous transluminal perfusion (CT). Methods 64 patients with primary liver cancer were randomly divided into two groups. Thirty-two of them were treated with TACE + percutaneous intratumoral injection of ethanol-lipiodol emulsion as the study group. Another 32 patients were treated as TACE alone. There was no significant difference in Child classification between the two groups (P> 0.05). Results Compared with the control group, the 1-year and 2-year survival rates of the study group and the control group were 96% / 78% and 81% respectively (P <0.05) / 48%. Conclusion PELI with TACE treatment of primary liver cancer than TACE alone has better clinical efficacy.